cost-effectiveness model (CEM Corporation)
90
Structured Review
CEM Corporation
cost-effectiveness model
Cost Effectiveness Model, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cost-effectiveness+model/cost+effectiveness+model/pmc10806544__openhrt___2023___002423supp001-45-34-36
Average 90 stars, based on 1 article reviews
Cost Effectiveness Model, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cost-effectiveness+model/cost+effectiveness+model/pmc10806544__openhrt___2023___002423supp001-45-34-36
Average 90 stars, based on 1 article reviews
cost-effectiveness model - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Clinical Proteomics:Article Title: Article Snippet: 89 Individual patient-level data (IPD) from 703 patients with PAF who were enrolled into Cryo90 FIRST, STOP AF First and EARLY-AF were used to derive prognostic equations to inform 91 input parameters for the Article Title: An economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a German healthcare payer perspective Article Snippet: Inputs for the current cost-effectiveness model ( Article Title: Tremelimumab and durvalumab with chemotherapy in first-line treatment for metastatic non-small cell lung cancer: a US-based cost-effectiveness analysis Article Snippet: The Article Title: Cost-effectiveness of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a US payer perspective. Article Snippet: • Compared with carboplatin-paclitaxel (CP), dostarlimab plus CP provided gains in quality-adjusted life-years (QALYs).. • Dostarlimab plus CP was cost-effective in both the dMMR/MSI-H and overall populations.. • The dMMR/MSI-H population had a 100 % probability of cost-effectiveness at a willingness-to-pay threshold of $150,000/QALY. Article Title: An economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a German healthcare payer perspective Article Snippet: Individual patient-level data from 703 participants with untreated PAF enrolled into three randomized clinical trials (Cryo-FIRST, STOP AF First and EARLY-AF) were used to derive parameters for the Article Title: A danish healthcare-focused economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation Article Snippet: The aim of this study was to develop a Article Title: Evaluating the accuracy of extrapolated overall survival for pembrolizumab: a comparison with long-term observed data in the Australian reimbursement context. Article Snippet: Background: Decisions about government funding for new medicines often rely on statistical models to predict how long patients will live (overall survival, OS) based on early trial data.. This study compared the accuracy of these predictions for the cancer drug pembrolizumab, using models preferred by pharmaceutical companies (Sponsors) and the Pharmaceutical Benefits Advisory Committee (PBAC), compared to real-world long-term follow-up (LTFU) data.. Research design and methods: We reviewed publicly available PBAC summary documents (PSDs) for all funding decisions on pembrolizumab up to November 2022. Article Title: Authors' response to a critical appraisal on "Assessing the cost-effectiveness of once-weekly somatrogon vs. daily somatropin for pediatric growth hormone deficiency". Article Snippet: Note that the overall trial efficacy data used in the |